Peptide Blog

All articles and shared info are for educational purposes only.

Latest Peptide Articles

BPC157: Molecular Characterization and Preclinical Research

BPC157: Molecular Characterization, Pleiotropic Signaling Mechanisms, and Preclinical Research

Body Protection Compound-157 (BPC157) is a synthetic pentadecapeptide composed of 15 amino acids. It is derived from a partial sequence of a gastric protective protein identified in gastric juice. The complete amino acid sequence of BPC157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. BPC157 has a molecular formula of C₆₂H₉₈N₁₆O₁₂ and a molecular weight of approximately 1419.5 g/mol (PubChem CID...

Copper Peptides: Molecular Characterization, Mechanistic Biology, and Emerging Research

Copper peptides are a class of naturally occurring and synthetically reproduced small peptide and copper ion complexes in which Cu²⁺ coordinates with specific amino acid sequences to form stable chelate structures. Three members of this class have received the most extensive research attention: glycyl-L-histidyl-L-lysine copper(II) (GHK-Cu), aspartyl-alanyl-histidyl-lysine copper(II) (DAHK-Cu), and alanyl-histidyl-lysine copper(II) (AHK-Cu). Each exhibits...

Modified GRF 1-29 and GHRP-2 Peptide Blend: Receptor Pharmacology, Somatotroph Signaling, and Neuroendocrine Research

The Modified GRF 1-29 and GHRP-2 peptide blend is a dual-component research formulation combining a stabilized growth hormone-releasing hormone (GHRH) analog with a synthetic ghrelin-mimetic hexapeptide. Modified GRF 1-29 (also designated CJC-1295 without DAC, or tetra-substituted GRF(1-29)) targets the GHRH receptor (GHRH-R), a Class B G protein-coupled receptor (GPCR) expressed on anterior pituitary somatotroph cells....
Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend Adipose Metabolism, GH Axis Modulation, and Receptor Signaling Research

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend: Adipose Metabolism, GH Axis Modulation, and Receptor Signaling Research

The Fragment 176-191, Modified GRF 1-29, and Ipamorelin peptide blend is a research-grade tri-component formulation combining three structurally and mechanistically distinct synthetic peptides. Fragment 176-191 (also designated hGH Frag 176-191, AOD-9604, or Tyr-hGH 177-191) is a synthetic C-terminal hexadecapeptide fragment of human growth hormone (hGH), engineered to isolate the lipolytic domain of the hGH polypeptide....
PNC-27 Structural Characterization, HDM-2-Dependent Membrane Targeting, and Selective Tumor Cell Necrosis

PNC-27: Structural Characterization, HDM-2-Dependent Membrane Targeting, and Selective Tumor Cell Necrosis

PNC-27 is a synthetic chimeric peptide engineered to engage the double minute-2 protein (HDM-2; the broader mammalian homolog of murine MDM-2) expressed on the plasma membranes of cancer cells. The peptide incorporates two functionally distinct domains: an HDM-2-binding sequence derived from the transactivating segment of the tumor suppressor protein p53 (residues 12-26), and a cell-penetrating...
AOD-9604: Research in Tissue Biology and Mammalian Oncology

AOD-9604: Molecular Characterization, Lipolytic Mechanisms, and Emerging Research in Tissue Biology and Mammalian Oncology

AOD-9604 is a synthetic hexadecapeptide fragment derived from the C-terminal region of hGH. It corresponds to residues 176–191 of the 191-amino acid hGH polypeptide, with the addition of a tyrosine residue at the N-terminus to support structural stability. The complete amino acid sequence of AOD-9604 is: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH, with a disulfide bond bridging the two cysteine...
Tesamorelin & Modified GRF 1-29 & Ipamorelin Blend: Growth Hormone Axis Pharmacology and Preclinical Research

Tesamorelin, Modified GRF 1-29, and Ipamorelin Peptide Blend: Growth Hormone Axis Pharmacology and Preclinical Research

The Tesamorelin, Modified GRF 1-29, and Ipamorelin peptide blend is a research-grade formulation combining three structurally distinct synthetic peptides, each engaging the growth hormone (GH) regulatory axis through pharmacologically discrete receptor mechanisms.  Two constituents - Tesamorelin and Modified GRF 1-29 - target the growth hormone-releasing hormone receptor (GHRH-R), a Class B G protein-coupled receptor (GPCR)...
Sermorelin, GHRP-6, and GHRP-2 Peptide Blend Receptor Pharmacology, Intracellular Signaling, and Neuroendocrine Research

Sermorelin, GHRP-6, and GHRP-2 Peptide Blend: Receptor Pharmacology, Intracellular Signaling, and Neuroendocrine Research

The Sermorelin & GHRP-6 & GHRP-2 peptide blend is a research-grade formulation designed to facilitate the study of integrated signaling within the somatotropin and ghrelin-related regulatory axes. This particular formulation combines a growth hormone-releasing hormone (GHRH) analog with two growth hormone secretagogue receptor (GHS-R) agonists, thereby enabling examination of parallel receptor engagement and downstream signaling...
Tesamorelin Molecular Characterization, Growth Hormone Axis Modulation, and Metabolic Research

Tesamorelin: Molecular Characterization, Growth Hormone Axis Modulation, and Metabolic Research

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It comprises a 44-amino acid sequence and is chemically designated as N-(trans-3-hexenoyl)-hGRF(1–44)NH₂ acetate. This designation reflects deliberate structural modifications at both the N-terminal and C-terminal regions of the peptide backbone. The N-terminal modification involves the addition of a trans-3-hexenoic acid moiety, while the C-terminal...
1 2 3 21